These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29356318)

  • 1. Standardisation of inactivated influenza vaccines-Learning from history.
    Wood JM; Weir JP
    Influenza Other Respir Viruses; 2018 Mar; 12(2):195-201. PubMed ID: 29356318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.
    Vasudevan A; Woerner A; Schmeisser F; Verma S; Williams O; Weir JP
    Influenza Other Respir Viruses; 2018 Mar; 12(2):250-258. PubMed ID: 29152878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
    Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
    Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of alternative potency assays for influenza vaccines requires clinical studies.
    Rowlen K
    Vaccine; 2015 Nov; 33(44):6025-6. PubMed ID: 26275481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
    Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the proficiency of single radial immunodiffusion assays for quality control of influenza vaccines in Korea.
    Choi Y; Lee S; Kwon SY; Lee Y; Park YK; Ban SJ
    Biologicals; 2017 Nov; 50():137-140. PubMed ID: 29111376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.
    Li C; Xu K; Hashem A; Shao M; Liu S; Zou Y; Gao Q; Zhang Y; Yuan L; Xu M; Li X; Wang J
    Hum Vaccin Immunother; 2015; 11(6):1351-6. PubMed ID: 25970793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
    Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
    Kuck LR; Byrne-Nash R; Gillis J; Bueter K; Couzens LK; Eichelberger MC; Rowlen KL
    Vaccine; 2018 May; 36(21):2937-2945. PubMed ID: 29699789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.
    Schmeisser F; Vasudevan A; Soto J; Kumar A; Williams O; Weir JP
    Influenza Other Respir Viruses; 2014 Sep; 8(5):587-95. PubMed ID: 25087462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen.
    Engelhardt OG; Edge C; Dunleavy U; Guilfoyle K; Harvey R; Major D; Newman R; Penn R; Skeldon S; Storey C; Wheeler J; Wood J; Minor P
    Vaccine; 2018 Jul; 36(29):4339-4345. PubMed ID: 29895503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring.
    Durous L; Julien T; Padey B; Traversier A; Rosa-Calatrava M; Blum LJ; Marquette CA; Petiot E
    Vaccine; 2019 Mar; 37(12):1614-1621. PubMed ID: 30773402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential effect of sub-micron level HA aggregates on influenza potency assays.
    Lemieux M; Lorbetskie B; Luebbert CC; Walrond L; Li C; Li X; Cyr T; Sauvé S; Johnston MJW; Farnsworth A
    Vaccine; 2019 Aug; 37(36):5276-5287. PubMed ID: 31337591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformationally selective biophysical assay for influenza vaccine potency determination.
    Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC
    Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion.
    Bodle J; Verity EE; Ong C; Vandenberg K; Shaw R; Barr IG; Rockman S
    Influenza Other Respir Viruses; 2013 Mar; 7(2):191-200. PubMed ID: 22583601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A latex agglutination assay to quantify the amount of hemagglutinin protein in adjuvanted low-dose influenza monovalent vaccines.
    Buffin S; Ikhelef N; Prudent J; Dubayle J; Nougarede N; Varenne MP; Moste C; Legastelois I
    J Virol Methods; 2018 Jan; 251():46-53. PubMed ID: 29030070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
    Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
    Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
    PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and qualification of the parallel line model for the estimation of human influenza haemagglutinin content using the single radial immunodiffusion assay.
    van Kessel G; Geels MJ; de Weerd S; Buijs LJ; de Bruijni MA; Glansbeek HL; van den Bosch JF; Heldens JG; van den Heuvel ER
    Vaccine; 2012 Jan; 30(2):201-9. PubMed ID: 22107849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings.
    Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC
    Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.